Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

An In-situ Detection for MicroRNA

NCT06529614
Recruiting
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

We designed a new in-site detection method for MicroRNA in the serum of patients with breast cancer.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Other: In-situ detection for Micro-RNA — a new in-situ detection methods for Micro-RNA

Primary Outcomes

  • Sensitivity and specificity of test (8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-20
Completion: 2025-11-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Principal Investigators:
  • Shabei Xu, Dr. (STUDY_DIRECTOR) - Tongji Hospital
Contact Information
Study Contact:
Lei Dou, Dr.
15171473498
616732045@qq.com
Lei Dou, Dr.
15171473498
616732045@qq.com
Tongji Hospital
Interventions
  • Other: In-situ detection for Micro-RNA — a new in-situ detection methods for Micro-RNA
Study Locations (1 sites)
Tongji Hospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: Healthy without serious diseases \- Exclusion Criteria: * situations that may affect the results
Conditions Metastatic Breast Cancer
Phase Not Applicable
Enrollment 800
Locations 26 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: \- Does the heterogeneity of HER2 expression level and spatial distribution in different tissues affect the efficacy of trastuzumab deruxtecan in metastatic breast cancer?

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Trastuzumab Deruxtecan — The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.

Primary Outcomes

  • Progression-free survival (PFS) (From date of T-DXd treatment initiation until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-10
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Principal Investigators:
  • Xiaoming Xie, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen University Cancer Center
Contact Information
Study Contact:
Xiaoming Xie, MD, PhD
86-020-87343806
xiexm@sysucc.org.cn
Yutian Zou, MD, PhD
86-020-87343806
zouyt@sysucc.org.cn
Amin H. Nassar, MD
amin.nassar@yale.edu
Yale Cancer Center
Interventions
  • Drug: Trastuzumab Deruxtecan — The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
Study Locations (26 sites)
Yale Cancer Center, New Haven, Connecticut 06510 United States
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215 United States
Fujian Cancer Hospital, Fujian Medical University, Fuzhou, Fujian China
The 10th Affiliated Hospital of Southern Medical University, Dongguan, Guangdong China
The First People's Hospital of Foshan, Foshan, Guangdong China
The Sixth Affiliated Hospital, School of Medicine, South China University of Technology., Foshan, Guangdong China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060 China
The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511400 China
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong China
The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: * Patients with advanced or locally unresectable breast cancer; * Treated with T-DXd (DS-8201, trastuzumab deruxtecan) regardless of line of therapy, HR, and HER2 expression level; * HER2 immunohistochemistry staining information of the primary lesion or metastatic/recurrent lesion; * Measurable lesions with treatment response results that can be evaluated through imaging examinations; * Able to follow up with the latest progression-free survival or overall survival. Exclusion Criteria: * Patients with missing basic clinical information or HER2 immunohistochemistry staining information; * Patients with missing pathological results for both primary and metastatic/recurrent lesions; * Patients with no measurable lesions and unable to evaluate T-DXd treatment response; * Discontinue T-DXd therapy for unacceptable adverse events or other reasons; * Patients lost to follow-up after T-DXd treatment.
Conditions Environmental Exposure, Health Behavior,...
Phase NA
Enrollment 200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will be based from a newly formed NHS service, the children's environmental health service. Participants will be children with a known chronic respiratory condition. Participants will undergo personal environmental exposure monitoring as well as home environmental assessments, before personalised exposure reports will be provided including a summary of their exposure and advising mitigation strategies based on exposure patterns and behaviours. The monitoring will be repeated after introduction of mitigation strategies. This will allow a comparison of the effectiveness of each method of mitigation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Exposure mitigations — Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure

Primary Outcomes

  • How effective is a specialist NHS environmental health clinic in reducing exposure to environmental contaminants in children with chronic respiratory disease, and what is the change in health outcomes. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-24
Completion: 2027-06
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Queen Mary University of London
Collaborators: Barts & The London NHS Trust
Principal Investigators:
  • Charles S Moorcroft, MBChB (PRINCIPAL_INVESTIGATOR) - Queen Mary University of London
Contact Information
Study Contact:
Charles S Moorcroft
07808061892
c.moorcroft@qmul.ac.uk
Abigail Whitehouse
a.whitehouse@qmul.ac.uk
Dr Jonathan Grigg
The Royal London Hospital
Interventions
  • Behavioral: Exposure mitigations — Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure
Study Locations (2 sites)
Queen Mary University of London, London, E1 2AT United Kingdom
The Royal London Hospital, London, E1 United Kingdom
Eligibility Criteria
Inclusion Criteria: * Parent/Guardian able to provide written informed consent Referral made by paediatric asthma team Child aged 4-17 years at the time of consent to study A diagnosis of a chronic respiratory condition (diagnosis by a medical professional) Contactable for regular follow up by the research team Reasonable level of English language Ability to engage with technology and devices used in the study Exclusion Criteria: * Inability to use the tools and devices in the research study Inability to visit the hospital for the initial hospital visit Inability to allow home environmental assessment
Conditions Diabetes Mellitus, Type 2, Diabetic Peri...
Phase Not Applicable
Enrollment 145
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to evaluate muscle fiber type composition in people with type 2 diabetes mellitus (T2DM) with a common complication of T2DM: diabetic peripheral neuropathy (DNP), specifically diabetic sensorimotor polyneuropathy. Researchers will also look into factors related to DNP: inflammation, the use of energy in the cell, nerve function and the tiny blood vessels in the muscle. The main question it aims to answer is: Are there differences in muscle fiber type composition between persons with T2DM with and without DNP, in comparison to sex and age-matched healthy peers? Participants will partake in the following tests: * electromyoneurography (EMNG): evaluation of nerve function, damage and repair; for diagnosis of DNP or other diseases of the nerves * blood analysis: researchers will measure insulin, blood sugar, lipid profile, inflammation * muscle biopsy in the calf (m. gastrocnemius): a doctor will take a small sample of muscle to evaluate the muscle shape and structure * mechanography: patients will perform functional tests (e.g. standing up from a chair), researchers will evaluate maximal power and maximal force of the muscles by jumping tests * questionnaires: on food intake, physical activity, smoking history, alcohol use, medical history * measurement of height, weight, and the comparison of the hip and waist circumference * peripheral Quantitative Computed Tomography (pQCT): scan of the calf for muscle density and bone density * electrocardiography (ECG): evaluation of electrical signals of the heart Researchers will compare (1) patients with T2DM with DNP, (2) patients with T2DM without DNP, and (3) healthy persons to see if there are differences in muscle fiber type composition

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Blood sampling — Fasting blood samples will be obtained.
  • Diagnostic Test: Electromyoneurography (EMNG) — Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
  • Procedure: Muscle biopsy — Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
  • Radiation: Quantitative peripheral computed tomography (qPCT) — A qPCT scan of the calf will be performed.
  • Device: Mechanography — Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
  • Diagnostic Test: Electrocardiography (ECG) — A 15-minute resting ECG will be performed.
  • Other: Questionnaires — Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
  • Other: Anthropometry — Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.

Primary Outcomes

  • Differences in muscle fiber type composition in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls. (At enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-12
Completion: 2025-11
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: true
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Ghent
Collaborators: University Ghent
Principal Investigators:
  • Bruno Lapauw (PRINCIPAL_INVESTIGATOR) - University Hospital, Ghent
Contact Information
Study Contact:
Cato Van De Looverbosch
0479922969
cato.vandelooverbosch@ugent.be
Cato Van De Looverbosch
0032479922969
cato.vandelooverbosch@ugent.be
Ghent University Hospital
Interventions
  • Diagnostic Test: Blood sampling — Fasting blood samples will be obtained.
  • Diagnostic Test: Electromyoneurography (EMNG) — Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
  • Procedure: Muscle biopsy — Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
  • Radiation: Quantitative peripheral computed tomography (qPCT) — A qPCT scan of the calf will be performed.
  • Device: Mechanography — Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
Study Locations (1 sites)
Ghent University Hospital, Ghent, 9000 Belgium
Eligibility Criteria
Inclusion Criteria: All participants: * Between 40-70 years of age * BMI between 18,5 - 35 kg/m2 Persons with T2DM: * More than 10-year clinical diagnosis of T2DM Exclusion Criteria: All participants: * Possible other causes of nerve impairment (vitamin B12 deficiency, excessive alcohol consumption, chemotherapy) * Immobilisation (1) \> 3 months in past history or (2) \> 4 weeks in past 6 months * Chronic conditions affecting the vital organs (New York Heart Association (NYHA) 3/4, Global Initiative for Obstructive Lung Disease (GOLD) 3/4, cystic fibrosis) * Hypogonadism * Inflammatory joint or intestinal diseases * Chronic muscle diseases * Active malignancy * Malnutrition disease, eating disorder or bariatric surgery * Medication use (anticoagulants, glucocorticoids, anti-androgen or anti-estrogen treatment) persons with T2DM: * Insufficient control of diabetes (HbA1c \>9%) Healthy controls: * Fasting glucose \> 100 mg/dl * HbA1c \> 5.7 %

Nitrous Oxide and EMOtional Cognition

NCT06557642
Recruiting
Conditions Depression
Phase NA
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to uncover the underlying neuropsychological mechanisms of nitrous oxide, which may be relevant to its reported antidepressant effects. In particular, the study is designed to determine whether nitrous oxide changes the way in which healthy volunteers aged 18-40 years remember negative autobiographical memories. The main question the study aims to answer is: • Does nitrous oxide interfere with the emotional aspects of negative autobiographical memories? Other neuropsychological effects will also be assessed (e.g., emotional processing, emotional memory, response inhibition, and cognitive flexibility). Researchers will compare ENTONOX (50% nitrous oxide: 50% oxygen) with medical air. Participants will: * Attend three research visits (screening, inhalation, follow-up) * Take part in a 30 minute inhalation session of ENTONOX or medical air * Complete a series of cognitive tasks * Finish a series of self-report questionnaires

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Entonox — 30 minute inhalation using demand valve and mouthpiece
  • Drug: Medical Air — 30 minute inhalation using demand valve and mouthpiece

Primary Outcomes

  • Changes in Emotional Ratings of Personal Memories (Memory Reconsolidation) (2 days before and 1 day after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-10
Completion: 2025-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oxford
Contact Information
Study Contact:
Catherine Harmer
01865 618200
catherine.harmer@psych.ox.ac.uk
Psychiatry Department
Interventions
  • Drug: Entonox — 30 minute inhalation using demand valve and mouthpiece
  • Drug: Medical Air — 30 minute inhalation using demand valve and mouthpiece
Study Locations (1 sites)
Psychiatry Department, Oxford, OX3 7JX United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18-40 years * Good vision and hearing * Willing and able to give informed consent * Body mass index (BMI) within the range of 18-35kg/m2 (This is to ensure we exclude underweight individuals who might have more substantial reactions to the nitrous oxide). * Sufficiently fluent in English to understand tasks * Willing to avoid drinking any alcohol from 3 days prior to Visit One until the end of Visit Three * Willing to avoid using recreational drugs for 3 months prior to Visit One and throughout the duration of the study Exclusion Criteria: * Receiving or seeking treatment for any mental health condition (covered in Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5 (SCID) assessment in screening procedures) * History of any mental health condition (covered in SCID assessment in screening procedures) * Attention deficit hyperactivity disorder (ADHD) requiring treatment with stimulant or other centrally-acting drugs * A positive drug test for any of the following: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, marijuana, methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), morphine, methaqualone, opiates, phencyclidine, propoxyphene, tricyclic antidepressants, tramadol, ketamine, oxycodone, cotinine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, synthetic marijuana, 6-mono-acetyl-morphine (6-MAM). * Regularly drink 14 or more units of alcohol a week * Any eye, throat or ear surgery or a medical procedure requiring intravenous injection or line into a vein in the last 6 months * A head injury causing concussion or unconsciousness in the past 6 months * A collapsed lung or lung surgery (e.g., pneumothorax) * A history of cardiac arrhythmias * Current injuries of the face or mouth (including ulcers or dental problems) * Dental surgery in the past month * Deep diving or scuba diving (which has a risk of decompression sickness) in past month * Pregnancy / intention to become pregnant during the study * Breastfeeding during the study * Asthma, emphysema or any medical condition that affects the lungs or breathing * Diagnosed vitamin B12 deficiency * Any use of recreational drugs in the last three months * Participation in any other drug study in the last three months * Participation in any other study with the same tasks in the last year OPTIONAL SLEEP STUDY ADD-ON Exclusion Criteria: * Unable to undergo cardiac monitoring * Unable to wear the sleep patch device for full monitoring period * Implanted neurostimulator
Conditions Major Depressive Disorder, Inflammatory ...
Phase NA
Enrollment 124
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to study how physical exercise works when applied to patients diagnosed with Major Depressive Disorder (MDD). The main questions it aims to answer are: * What are the antiinflammatory and oxidative stress and neural mechanisms involved in the antidepressant effects of exercise? * How effective is a physical exercise program in MDD patients in real-life conditions? The experimental group will receive an exercise intervention as an add-on to their usual treatment (antidepressant treatment prescribed by the attending specialist). Researchers will compare to a control group, which will only receive standard treatment (antidepressant treatment prescribed by the attending specialist) and will be instructed to not change their usual physical activity. The aim is to see if a physical exercise intervention would induce a significant improvement in depressive symptoms and which mechanisms are responsible for this result.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Physical Exercise — Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week. Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes.
  • Drug: Antidepressant medication (ADM) — Patients will receive their standard antidepressant treatment prescribed by their psychiatrist.

Primary Outcomes

  • Inflammatory and oxidative stress biomarkers (1. Before randomization; 2. 12-weeks after the beggining of intervention; 3. 1 year after randomization)
  • Brain imaging (1. Before randomization; 2. 12 Weeks after the beggining of intervention)
  • Clinical evaluation (1. Before Randomization; 2. 12 Weeks after the beggining of intervention; 3. 1 Year after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-21
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Collaborators: Hospital Universitario La Paz, Hospital Universitario Ramon y Cajal, Hospital Universitario Principe de Asturias, Quirón Madrid University Hospital, Universidad Autonoma de Madrid, Centro de Investigación Biomédica en Red de Salud Mental, Puerta de Hierro University Hospital
Principal Investigators:
  • Pilar López García, PhD (PRINCIPAL_INVESTIGATOR) - Universidad Autonoma de Madrid
Contact Information
Study Contact:
Javier Gómez Cumplido, PT, MSc
(+34) 633467602
javier.gomezc@uam.es
Pilar López García, PhD
(+34) 91 497 54 48
p.lopez@uam.es
María Vicens Poveda
mvicenspoveda@gmail.com
Hospital Universitario Príncipe de Asturias
Interventions
  • Other: Physical Exercise — Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week. Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes.
  • Drug: Antidepressant medication (ADM) — Patients will receive their standard antidepressant treatment prescribed by their psychiatrist.
Study Locations (5 sites)
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid 28805 Spain
Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid 28222 Spain
Hospital Universitario de La Princesa, Madrid, 28006 Spain
Hospital Universitario Ramón y Cajal, Madrid, 28034 Spain
Hospital Universitario La Paz, Madrid, 28046 Spain
Eligibility Criteria
Inclusion Criteria: * A diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria (through the Mini International Neuropsychiatric Interview (MINI) * Severity of depression according to the Hamilton Depression Rating Scale 17 items (HAM-D17): minimum of 14 cut-off score of moderate depression. * Outpatient clinical care. * Current antidepressant treatment that will be maintained during the 12 weeks of the physical exercise intervention. Exclusion Criteria: * Diagnosis of any axis I diagnosis except for MDD; * Contraindications for Magnetic Resonance Imaging. * Antiinflammatory treatments or antibiotics within the week before randomisation. * Vaccines within the month before randomisation. * Fever (\>38ºC) at the moment of study entry. * Pregnant women. * Alcohol or drug abuse.
Conditions Pulmonary Artery Hypertension
Phase Not Applicable
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To assess whether changes in electrical impedance - measured using an electrical impedance tomography (EIT) chest belt - can be used to derive changes in pulmonary artery pressure (PAP) in critically ill patients when compared to invasive gold-standard PAP measured using pulmonary artery catheter (PAC).

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Device: Electrical impedance tomography — In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.

Primary Outcomes

  • Mean difference between EIT-derived and PAC-measured changes in pulmonary artery pressure (Up to 48 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-05
Completion: 2027-08-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insel Gruppe AG, University Hospital Bern
Collaborators: CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Principal Investigators:
  • Kaspar F Bachmann, MD (PRINCIPAL_INVESTIGATOR) - Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • Carmen A Pfortmueller, MD (STUDY_DIRECTOR) - Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Contact Information
Study Contact:
Kaspar F Bachmann, MD
+41 31 632 21 11
kaspar.bachmann@faculty.unibe.ch
Carmen A Pfortmueller, MD
+41 31 632 21 11
intensivmedizin@insel.ch
Inselspital Bern, Universitätsklinik für Intensivmedizin
Kaspar F Bachmann, MD
Inselspital Bern, Universitätsklinik für Intensivmedizin
Interventions
  • Device: Electrical impedance tomography — In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
Study Locations (1 sites)
Inselspital Bern, Universitätsklinik für Intensivmedizin, Bern, 3010 Switzerland
Eligibility Criteria
Inclusion criteria: * Age ≥ 18-year-old. * Intubated patients in the ICU with clinical decision to monitor PAP and cardiac output using a PAC. Exclusion criteria: * Patients with implanted or external thoracic electronic devices (e.g., pacemaker) or thoracic metal implants. * Known pregnancy or lactating patients. * Open lung injuries or pneumothorax. * Open wounds, drainages, burns or rashes of the upper thorax. * Estimated thoracic perimeter smaller than 66 cm or larger than 134 cm. * Known allergies to wound dressings or adhesives (e.g., gel electrodes)
Conditions Pancreatic Ductal Adenocarcinoma, Non-sm...
Phase PHASE1
Enrollment 162
Locations 29 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: [68Ga]Ga-NNS309 — Radioligand imaging agent
  • Drug: [177Lu]Lu-NNS309 — Radioligand therapy

Primary Outcomes

  • Number of patients with dose limiting toxicities of [177Lu]Lu-NNS309 (From start of study treatment until 6 weeks or 4 weeks after, depending on dosing schedule)
  • Incidence and severity of adverse events and serious adverse events of [177Lu]Lu-NNS309 (From start of study treatment until completion of the 36 month follow up, assessed up to approximately 42 months)
  • Dose modifications for [177Lu]Lu-NNS309 (From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks)
  • Dose intensity for [177Lu]Lu-NNS309 (From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-15
Completion: 2031-01-16
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Quenteeria Mooney
qmooney@uabmc.edu
Uni of Alabama at Birmingham
Interventions
  • Drug: [68Ga]Ga-NNS309 — Radioligand imaging agent
  • Drug: [177Lu]Lu-NNS309 — Radioligand therapy
Study Locations (29 sites)
Uni of Alabama at Birmingham, Birmingham, Alabama 35249 United States
University of California LA, Los Angeles, California 90095 United States
Stanford University Medical Center, Palo Alto, California 94304 United States
Mayo Clinic Jacksonville, Jacksonville, Florida 32224 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
BAMF Health, Grand Rapids, Michigan 49503 United States
Mayo Clinic Rochester, Rochester, Minnesota 55905 United States
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas 77030 United States
University Of Washington, Seattle, Washington 98109 United States
Novartis Investigative Site, Brussels, 1000 Belgium
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Patients with one of the following indications: * Locally advanced unresectable or metastatic PDAC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy * Locally advanced unresectable or metastatic NSCLC without any actionable genomic alterations with disease progression following, or intolerance to chemotherapy and immunotherapy, unless patient was ineligible to receive such therapy, or locally advanced unresectable or metastatic NSCLC with an actionable genomic alteration with disease progression following, or intolerance to targeted therapy, unless patient was ineligible to receive such therapy * Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular BC with disease progression following, or intolerance to, at least 2 lines of therapy, unless patient was ineligible to receive such therapy * Locally advanced unresectable or metastatic TNBC with disease progression following, or intolerance to, at least 2 lines of therapy, unless patient was ineligible to receive such therapy * Locally advanced or metastatic unresectable CRC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy. Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status must also have had disease progression following, or intolerance to immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy * Patients must have lesions showing 68Ga-NNS309 uptake Exclusion Criteria: * Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L, hemoglobin \< 9 g/dL, or platelet count \< 100 x 10\^9/L * QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec * Calculated estimated glomerular filtration rate \< 60 mL/min/1.73m2 * Unmanageable urinary tract obstruction or urinary incontinence * Radiation therapy within 4 weeks prior to the first dose of \[177Lu\]Lu-NNS309 Other protocol-defined inclusion/exclusion criteria may apply.
Conditions Type 2 Diabetes, Diabetes With Diabetic ...
Phase PHASE4
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetic cardiac autonomic neuropathy (DCAN) is a common chronic complication that reduces survival in patients with diabetes. Epidemiological surveys have shown that the prevalence of DCAN is 25-75% in people with type 2 diabetes. The onset of DCAN is insidious and easy to be ignored in the early stage. With the progression of the disease, the following clinical symptoms gradually appear, including reduced heart rate variability, exercise intolerance, resting tachycardia, orthostatic hypotension, painless myocardial infarction and even sudden death, which seriously endanger the life and health of type 2 diabetes patients. Existing literature has shown that glucagon-like peptide-1 receptor agonist (GLP-1RA) can improve diabetic peripheral neuropathy and diabetic cognitive dysfunction, but there are few studies on improving diabetic autonomic neuropathy. Insulin resistance is an important risk factor for DCAN. Patients with type 2 diabetes are characterized by insulin resistance, and GLP-1RA is recognized as a drug to improve insulin resistance and control blood sugar in patients with diabetes. In this study, GLP-1RA was used to intervene patients with type 2 diabetes, and the changes in blood sugar control and insulin resistance status of patients were followed up. Special attention was paid to the improvement of autonomic neuropathy in diabetic patients.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Glucagon-like peptide-1 receptor agonist:Semaglutide — The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention

Primary Outcomes

  • heart rate variability(HRV) (baseline and 12 weeks later)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-06-13
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Principal Investigators:
  • jianbo Li, MD/PhD (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital,Nanjing Medical University,China
Contact Information
Study Contact:
jianbo Li, MD/PhD
13951750648
ljbzjlx18@aliyun.com
li wang
15061040299
wangli08010923@163.com
the First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: Glucagon-like peptide-1 receptor agonist:Semaglutide — The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
Study Locations (1 sites)
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029 China
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18-70 years 2. Patients with T2DM who meet the diagnostic guidelines 3. The patient signed the relevant informed consent form 4. Being overweight or obese Exclusion Criteria: 1. \<18 years old 2. Pregnant or lactating women 3. Acute and chronic pancreatitis 4. Recent acute complications of diabetes 5. Arrhythmia or taking drugs that affect heart rate 6. Thyroid disease 7. Severe organ dysfunction 8. Denial of informed consen
Conditions Obesity, Hypertension
Phase EARLY_PHASE1
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Angiotensin-(1-7) — This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
  • Drug: Saline — Saline will be used as the placebo comparator.

Primary Outcomes

  • Change in Muscle Sympathetic Nerve Burst Rate (120 minutes)
  • Change in Brachial Artery Diameter (120 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-01-23
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Amy Arnold, PhD (PRINCIPAL_INVESTIGATOR) - Pennsylvania State University College of Medicine
Contact Information
Study Contact:
Aimee Cauffman, RN
717-531-1617
acauffman@pennstatehealth.psu.edu
Amy Arnold, PhD
717-531-3674
aarnold5@pennstatehealth.psu.edu
Amy Arnold, PhD
717-531-3674
aarnold5@pennstatehealth.psu.edu
Penn State Milton S. Hershey Medical Center
Interventions
  • Drug: Angiotensin-(1-7) — This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
  • Drug: Saline — Saline will be used as the placebo comparator.
Study Locations (1 sites)
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033 United States
Eligibility Criteria
Inclusion Criteria: * Men and women of all races * Age 18 to 65 years * Body mass index (BMI) between 30-45 kg/m2 * Pre-hypertension (defined as two or more seated blood pressure readings \>120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings \>130/80 mmHg or use of antihypertensive medications) * Capable of giving informed consent * Fluent in written and spoken English * Satisfactory history and physical exam Exclusion Criteria: * Age ≤ 17 or ≥ 66 years * Taking more than two antihypertensive medications * Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease) * Pregnant or nursing women * Women taking hormone replacement therapy within 6 months * Decisional impairment * Prisoners * Alcohol or drug abuse * Current smokers * Highly trained athletes * Subjects with \>5% weight change in the past 3 months * BMI \> 45 kg/m2 * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications) * History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack) * History or presence of immunological or hematological disorders * Impaired hepatic function \[aspartate aminotransferase (AST) or alanine transaminase (ALT) levels \>2 times upper limit of normal range\] * Impaired renal function (serum creatinine \>2.0 mg/dl) * Anemia * Treatment with drugs increasing sympathetic activity \[e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants\] * Treatment with phosphodiesterase-5 inhibitors * Treatment with anticoagulants (e.g. warfarin) * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month) * Treatment with any investigational drug in the 1-month preceding the study * Inability to give, or withdraw, informed consent
Conditions Depression
Phase NA
Enrollment 525
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test ways to help people improve their health and manage their medication for depression. This study will measure both medication adherence and depression outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: Arm 1 intervention — This description is blinded.
  • Behavioral: Arm 2 Intervention — This description is blinded

Primary Outcomes

  • Depression symptom response 12 weeks (12 weeks from baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-19
Completion: 2029-03-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 525 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Contact Information
Study Contact:
Steven C Marcus, PhD
215-573-7941
marcuss@upenn.edu
Cadence F Bowden, MSW, MPH
215-898-9995
cbowden@upenn.edu
University of Pennsylvania Health System
Interventions
  • Behavioral: Arm 1 intervention — This description is blinded.
  • Behavioral: Arm 2 Intervention — This description is blinded
Study Locations (1 sites)
University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Penn Medicine primary care outpatients * Clinical diagnosis of major depressive disorder * A score of 10+ on the Patient Health Questionnaire 9 (PHQ-9) * Age 21 to 64 years at the time of study entry * Prescribed an antidepressant by their primary care clinician * Express interest in taking antidepressant medication * Own a cell phone * Capable of using the electronic pill bottle * English-speaking Exclusion Criteria: * Treated with antidepressants in the past 90 days * Pregnant or breastfeeding * An active substance use disorder other than nicotine * A lifetime history of treatment for bipolar disorder or schizophrenia * Hospital admission or emergency department visit for suicidal symptoms in the past year * Lack capacity to provide informed consent * Using antidepressant more than 10 days at baseline assessment
Conditions Breast Cancer Survivorship
Phase PHASE2
Enrollment 120
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Adapted Patient Priorities Care (PPC) approach — Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
  • Other: Usual Care — Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.

Primary Outcomes

  • Treatment burden as assessed by the treatment burden questionnaire (TBQ) (baseline)
  • Treatment burden as assessed by the treatment burden questionnaire (TBQ) (3 months)
  • Treatment burden as assessed by the treatment burden questionnaire (TBQ) (6 months)
  • Health status as assessed by the Functional Assessment of Cancer Therapy - Breast (FACT-B) (baseline)
  • Health status as assessed by the Functional Assessment of Cancer Therapy - Breast (FACT-B) (3 months)
  • Health status as assessed by the Functional Assessment of Cancer Therapy - Breast (FACT-B) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-02
Completion: 2027-06-01
Eligibility
Age: 65 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA)
Principal Investigators:
  • Dana E. Giza, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Dana E. Giza, MD
(713) 500-6087
Dana.E.Giza@uth.tmc.edu
Justun Holder
713-500-9438
Justun.B.Holder@uth.tmc.edu
UT Physicians Center for Healthy Aging Bellaire
Justun Holder, RC III
713-500-9438
Justun.B.Holder@uth.tmc.edu
UT Physicians Family Medicine Bayshore
Interventions
  • Behavioral: Adapted Patient Priorities Care (PPC) approach — Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
  • Other: Usual Care — Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
Study Locations (3 sites)
UT Physicians Center for Healthy Aging Bellaire, Bellaire, Texas 77401 United States
UT Physicians Family Medicine Bayshore, Houston, Texas 77006 United States
Memorial Hermann Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * able to write and speak English * Stage DCIS/I/II/III breast cancer diagnosis * 3 months from active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment) up to 10 years since completing treatment * ≥3 documented comorbidities by chart review, or taking ≥10 medications, have ≥ 1 hospitalization over the past year, ≥ 2 emergency department visits over the past year, seen by \> 2 specialists over the past year * able to provide consent Exclusion Criteria: * currently on active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment)